2023 University of Kansas Breast Cancer Year in Review Conference Learners' Notification
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
​
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council forContinuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Amedco LLC designates this live activity for a maximum of 4.50 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
Amedco LLC designates this activity for a maximum of 4.50 knowledge-based CPE contact hours.
Nurses
Amedco LLC designates this activity for a maximum of 4.50 ANCC contact hours.
​
Objectives - After Attending This Program You Should Be Able To
-
Determine best application of new targeted therapies in patients with early-stage and metastatic disease
-
Discuss the advances in systemic therapy likely to change current practices for treatment of breast cancer
-
Know how to utilize genomic tools for systemic therapy decision making and prediction of treatment response.
​
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5) All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.
